KLK3 and posterior cortical atrophy: The 13-year risk of any PCa and clinically significant PCa incidence was highest among men with a baseline PSA level of 4.00 ng/mL or greater (any PCa: 53.7%; 95% CI, 48.6%-58.8%; clinically significant PCa: 29.5%; 95% CI, 24.2%-34.8%).